Davis Todd C 4

What Happened

• Todd C. Davis, a director of Palvella Therapeutics, received a grant described as 3,000 derivative shares (an option/award) on 2026-06-10. The reported per-share acquisition price is $0.00, and the reported total value of the grant is $0.00.

Key Details

• Transaction date: 2026-06-10; Filing date: 2026-06-12.
• Transaction type: Grant / award of derivative securities (code A on the Form 4).
• Amount: 3,000 shares/options acquired at $0.00 (reported value $0).
• Shares owned after transaction: Not specified in the filing.
• Footnote: The award vests upon the earlier of (i) the first anniversary of the grant date or (ii) the issuer’s next annual meeting of stockholders, subject to continued service by Mr. Davis through the applicable vesting date.
• Filing timeliness: Filed two days after the transaction date (within the typical 2-business-day Form 4 window).

Context

• This is a grant/award (not an open-market buy or a sale). Such grants compensate or retain executives/directors and do not by themselves indicate buying or selling activity in the open market. The award’s vesting schedule means the shares/options are subject to forfeiture if the director leaves before vesting.